Yisheng Lai

State Key Laboratory Of Natural Medicines, Jiangsu Key Laboratory Of Drug Discovery For Metabolic Disease
Nanjing, 210009, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Discovery of Pyrrolo[1',2':1,6]pyrimido[5,4-c]pyridazin-6(5H)-one Derivatives as Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Inhibitors.

Discovery of Pyrrolo[1',2':1,6]pyrimido[5,4-c]pyridazin-6(5H)-one Derivatives as Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Inhibitors.

Journal: Journal of medicinal chemistry

Published: May 26, 2026

1-(3,4-Diaminophenyl)-1H-pyrrole-2-carboxylic acids as potent apo-IDO1 inhibitors exhibiting efficacy in syngeneic tumor mouse models.

1-(3,4-Diaminophenyl)-1H-pyrrole-2-carboxylic acids as potent apo-IDO1 inhibitors exhibiting efficacy in syngeneic tumor mouse models.

Journal: European journal of medicinal chemistry

Published: July 24, 2025

Discovery of Novel 5-(Pyridazin-3-yl)pyrimidine-2,4(1H,3H)-dione Derivatives as Potent and Orally Bioavailable Inhibitors Targeting Ecto-5'-nucleotidase.

Discovery of Novel 5-(Pyridazin-3-yl)pyrimidine-2,4(1H,3H)-dione Derivatives as Potent and Orally Bioavailable Inhibitors Targeting Ecto-5'-nucleotidase.

Journal: Journal of medicinal chemistry

Published: October 10, 2024

Discovery of novel substituted pyridine carboxamide derivatives as potent allosteric SHP2 inhibitors.

Discovery of novel substituted pyridine carboxamide derivatives as potent allosteric SHP2 inhibitors.

Journal: European journal of medicinal chemistry

Published: June 18, 2024

Targeting MutT Homolog 1 (MTH1) for Breast Cancer Suppression by Using a Novel MTH1 Inhibitor MA-24 with Tumor-Selective Toxicity.

Targeting MutT Homolog 1 (MTH1) for Breast Cancer Suppression by Using a Novel MTH1 Inhibitor MA-24 with Tumor-Selective Toxicity.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: January 20, 2024

Structure-Based Drug Design of Novel Triaminotriazine Derivatives as Orally Bioavailable IDH2R140Q Inhibitors with High Selectivity and Reduced hERG Inhibitory Activity for the Treatment of Acute Myeloid Leukemia.

Structure-Based Drug Design of Novel Triaminotriazine Derivatives as Orally Bioavailable IDH2R140Q Inhibitors with High Selectivity and Reduced hERG Inhibitory Activity for the Treatment of Acute Myeloid Leukemia.

Journal: Journal of medicinal chemistry

Published: September 14, 2023

IDO1 Inhibition Promotes Activation of Tumor-intrinsic STAT3 Pathway and Induces Adverse Tumor-protective Effects.

IDO1 Inhibition Promotes Activation of Tumor-intrinsic STAT3 Pathway and Induces Adverse Tumor-protective Effects.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: August 15, 2023

Correction: Apo-Form Selective Inhibition of IDO for Tumor Immunotherapy.

Correction: Apo-Form Selective Inhibition of IDO for Tumor Immunotherapy.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: May 17, 2023

Design, synthesis, and evaluation of 4(1H)-quinolinone and urea derivatives as KRASG12C inhibitors with potent antitumor activity against KRAS-mutant non-small cell lung cancer.

Design, synthesis, and evaluation of 4(1H)-quinolinone and urea derivatives as KRASG12C inhibitors with potent antitumor activity against KRAS-mutant non-small cell lung cancer.

Journal: European journal of medicinal chemistry

Published: July 29, 2022

Combination of apatinib with apo-IDO1 inhibitor for the treatment of colorectal cancer.

Combination of apatinib with apo-IDO1 inhibitor for the treatment of colorectal cancer.

Journal: International immunopharmacology

Published: June 27, 2022

Apo-Form Selective Inhibition of IDO for Tumor Immunotherapy.

Apo-Form Selective Inhibition of IDO for Tumor Immunotherapy.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: September 30, 2021

Design, Synthesis, and Evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo.

Design, Synthesis, and Evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo.

Journal: Journal of medicinal chemistry

Published: May 26, 2021

Showing 1-12 of 50

Last Updated: 09/26/2026